- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01795898
An Efficacy and Safety Study of Fentanyl Transdermal Patch in Filipino Participants With Osteoarthritis and Chronic Low Back Pain
June 10, 2013 updated by: Janssen Pharmaceutica
Efficacy, Safety and Quality of Life Outcome of Fentanyl Transdermal Patch (Durogesic-D-Trans) Among Filipino Patients With Osteoarthritis and Chronic Low Back Pain
The purpose of this study is to evaluate the efficacy and safety of fentanyl among Filipino participants with osteoarthritis (disorder which is seen mostly in older persons in which the joints become painful and stiff) and chronic (lasting a long time) low back pain.
Study Overview
Detailed Description
This is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded") single-arm and prospective study (study following participants forward in time) of fentanyl in participants with osteoarthritis and Chronic low back pain with moderate (medium level of seriousness) and severe (very serious, life threatening) pain levels.
Participants will be treated with fentanyl transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) starting with 12.5 microgram (mcg) dose of fentanyl.
The dose will be increased on Day 3, if needed, by 12.5 mcg.
Dose adjustments will be done every 3 days.
Maximum of 50 mcg dose of fentanyl will be allowed.
Participants will be evaluated for pain levels and quality of life using Brief pain inventory (BPI) score and Clinical global impression-severity (CGI-S) score.
Tramadol 50 milligram tablet at a maximum of 6 tablets per day will be used as supplemental doses of analgesic (drug used to control pain).
Participants' safety will be monitored through out the study.
Study Type
Interventional
Enrollment (Actual)
237
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Quezon City, Philippines
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants diagnosed with osteoarthritis and chronic low back pain
- 3 months of persistent moderate to severe pain levels
- More than 3 times a week frequency or daily moderate to severe pain
- Moderate to severe pain at Baseline (at least a score of 4 in the 11-point numerical pain scale) Exclusion Criteria
- History of allergy to fentanyl transdermal patch or its components and history of illicit drug use for the past 3 months
- Active skin disease preventing application of the transdermal system
- Chronic pulmonary disease (lung disorder)
- Participants susceptible to intracranial (inside the skull) effects of carbon dioxide retention
- Pregnant and breastfeeding mothers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fentanyl transdermal patch
Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days.
The patches will be replaced every 3 days (Day 3, 7 and 10).
|
Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days.
The patches will be replaced every 3 days (Day 3, 7 and 10).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Brief Pain Inventory (BPI) Severity Score at Day 30
Time Frame: Baseline and Day 30
|
BPI is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions.
BPI- severity consists of 4 questions (items) that assess pain intensity (worst, least, average, right now).
Each question (item) is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'.
Measure can be scored by item, with lower scores being indicative of less pain or pain interference.
Change: Score at Day 30 minus score at Baseline.
|
Baseline and Day 30
|
Change From Baseline in Brief Pain Inventory (BPI) Interference Score at Day 30
Time Frame: Baseline and Day 30
|
BPI is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions.
BPI-interference consists of 7 questions (items) that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life).
Each question (item) is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'.
Measure can be scored by item, with lower scores being indicative of less pain or pain interference.
Change: Score at Day 30 minus score at Baseline.
|
Baseline and Day 30
|
Number of Participants Requiring Rescue Medication
Time Frame: Day 30
|
Rescue medications are periodic supplemental doses of analgesic which might be required to control pain.
Tramadol 50mg tablet at a maximum of 6 tablets per day was used as standard rescue medication.
|
Day 30
|
Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score: Clinician
Time Frame: Day 30
|
CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
|
Day 30
|
Number of Participants With Clinical Global Impression-Improvement (CGI-I) Score: Participant
Time Frame: Day 30
|
CGI-I is a 7-point scale that requires the Participant to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
|
Day 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
February 19, 2013
First Submitted That Met QC Criteria
February 19, 2013
First Posted (Estimate)
February 21, 2013
Study Record Updates
Last Update Posted (Estimate)
July 15, 2013
Last Update Submitted That Met QC Criteria
June 10, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Back Pain
- Low Back Pain
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Fentanyl
Other Study ID Numbers
- CR015268
- FENPAI4074
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Fentanyl
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)CompletedPeer Review, ResearchUnited States
-
Alexza Pharmaceuticals, Inc.Completed
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
University of Texas Southwestern Medical CenterCompletedPregnancyUnited States
-
Samuel Lunenfeld Research Institute, Mount Sinai...Terminated
-
University of PatrasUnknownStillborn Caesarean SectionGreece
-
Janssen Research & Development, LLCCompleted
-
Ente Ospedaliero Cantonale, BellinzonaNot yet recruiting
-
Johns Hopkins UniversityCompletedIntracranial SurgeryUnited States